Formation of HIV-1 envelope-hepatitis B core antigen hybrids with high affinity for CD4.
We have identified an acceptor site on HIV gp120, where foreign protein sequences can be inserted while retaining the native conformation of gp120. The resulting hybrids showed dual antigenicity, normal glycosylation, and high affinity binding of the CD4 receptor. This site allows insertion of highly immunogenic proteins such as core antigen of hepatitis B virus. By combining the immunogenicity of the carrier protein with the antigenicity of gp120, these hybrids may lead to modified HIV-1 antigens with enhanced immunogenicity.
Patterson
L J
LJ
Laboratory of Immunoregulation, Office of Vaccine Research and Review, FDA/National Institutes of Health, NIH Campus Bldg. 29, Bethesda, MD 20892, USA.
Aberdeen
A
A
Kone
J
J
Haben
M
M
Raymond
M
M
Berkower
I
I
D016915:AIDS Vaccines / Q000235:genetics* / Q000276:immunology; D000818:Animals; D001665:Binding Sites; D015153:Blotting, Western; D015704:CD4 Antigens / Q000378:metabolism*; D016860:CD4 Immunoadhesins / Q000378:metabolism; D002846:Chromatography, Affinity; D004306:Dose-Response Relationship, Immunologic; D015870:Gene Expression; D015699:HIV Envelope Protein gp120 / Q000235:genetics*; D006512:Hepatitis B Core Antigens / Q000235:genetics* / Q000378:metabolism; D051379:Mice; D008815:Mice, Inbred Strains; D011485:Protein Binding; D017434:Protein Structure, Tertiary / Q000235:genetics; D011993:Recombinant Fusion Proteins / Q000235:genetics* / Q000276:immunology / Q000378:metabolism*; D014614:Vaccines, Synthetic / Q000235:genetics / Q000276:immunology / Q000378:metabolism; D014616:Vaccinia virus / Q000235:genetics
D016915:AIDS Vaccines; D015704:CD4 Antigens; D016860:CD4 Immunoadhesins; D015699:HIV Envelope Protein gp120; D006512:Hepatitis B Core Antigens; D011993:Recombinant Fusion Proteins; D014614:Vaccines, Synthetic